A narrative review on progress and development of anti-CD36 antibody detection

Abstract

Immune-mediated thrombocytopenia occurs due to alloantibodies against platelet antigens, such as the ABO blood group antigens, HLA class I, and human platelet antigens (HPA). In recent years, more than 30 HPA have been identified (https://www.versiti.org/medicalprofessionals/precision-medicine-expertise/plateletantigen-database/hpa-gene-database). Among them, alloantibodies against the HPA-1a formed by point mutation (Leu33Pro) on platelet glycoprotein (GP) IIIa (known as β3 integrin) are responsible for most cases of alloimmune thrombocytopenia in Caucasians (1). However, foetal and neonatal alloimmune thrombocytopenia (FNAIT) caused by anti-HPA-1a antibodies has not been well recognized in other populations. Interestingly, accumulating evidence indicates that immune-mediated thrombocytopenia caused Review Article